Dermata Therapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Balance Sheet Details (Tables)

12 Months Ended

Dec. 31, 2023

	As of December 31,
	2023		2022
Prepaid expenses and other current assets
Prepaid insurance	$	426,413	$	586,407
Prepaid research and development costs		91,232		92,581
Prepaid other		14,498		11,604
Interest receivable		8,356		12,602
Total prepaid expenses and other current assets	$	540,499	$	703,194

Accrued and other current liabilities
Accrued research and development costs	$	40,596	$	254,787
Accrued compensation and benefits		716,490		170,389
Accrued other		502		756
Total accrued and other current liabilities	$	757,588	$	425,932